<div id="readability-page-1"><p>In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Pyxis Oncology, with a price target of <span id="expert-recommendation-target">$9.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Willey is a 4-star analyst with an average return of <span>7.6%</span> and a 41.89% success rate. Willey covers the Healthcare sector, focusing on stocks such as Zymeworks, Nurix Therapeutics, and Pyxis Oncology.</p> <p>In addition to Stifel Nicolaus, Pyxis Oncology also received a Buy from LifeSci Capital’s Sam Slutsky in a report issued today. However, yesterday, William Blair reiterated a Hold rating on Pyxis Oncology (NASDAQ: PYXS).</p></div>

PYXS

<p>Stifel Nicolaus analyst Stephen Willey maintained a Buy rating for Pyxis Oncology with a $9.00 price target. Willey, a 4-star analyst on TipRanks, focuses on the Healthcare sector. LifeSci Capital's Sam Slutsky also issued a Buy rating, while William Blair reiterated a Hold rating for Pyxis Oncology.</p>

Stifel Nicolaus Sticks to Its Buy Rating for Pyxis Oncology (PYXS)